Press releases
- Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
- Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
- Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
More ▼
Key statistics
On Monday, Blueprint Medicines Corp (2L9:DUS) closed at 106.30, -3.32% below its 52-week high of 109.95, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 103.95 |
---|---|
High | 106.30 |
Low | 103.90 |
Bid | 106.30 |
Offer | 108.20 |
Previous close | 104.35 |
Average volume | 136.10 |
---|---|
Shares outstanding | 62.62m |
Free float | 62.04m |
P/E (TTM) | -- |
Market cap | 7.16bn USD |
EPS (TTM) | -4.82 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 18:30 BST.
More ▼